Femasys Inc.
FEMY · Price history
Price at last available close
$1.37
−$1.01 (-42.44%) 1M
2026-10-27
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Femasys Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 13, 2026. A research update is not a new financial filing.
Who they are
Femasys Inc., a biomedical company established in 2004 and based in Suwanee, Georgia, primarily targets the women's healthcare market within the United States. The firm's innovative product line includes permanent contraceptive solutions such as FemBloc and FemChec, alongside FemaSeed, which is an artificial insemination offering. For diagnostic purposes, Femasys provides FemCerv, a biopsy device utilized for endocervical curettage, and FemEMB, a product candidate intended for endometrial sampling to assist in the detection of uterine cancer.
How they make money
Femasys Inc. is a biomedical company that generates revenue primarily through the development and commercialization of medical devices and diagnostic products for women's reproductive health. The company sells its proprietary products, such as FemVue and FemaSeed, to healthcare providers and fertility centers, while also pursuing regulatory approvals to expand its market reach for non-surgical permanent birth control solutions.
Products & services
Femasys develops and markets medical devices including FemVue for ultrasound-based fallopian tube assessment, FemaSeed for intratubal insemination, and the FemBloc delivery system for non-surgical permanent birth control, alongside companion diagnostic products like FemCath and FemChec.
Brands & revenue mix
Ultrasound-based fallopian tube assessment device.
Separate brand revenue is not available in this research.Source
First-line intratubal insemination product.
Separate brand revenue is not available in this research.Source
Non-surgical permanent birth control delivery system.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
Customer concentration
No quantified customer-concentration disclosure is available in the current saved research.
Suppliers, materials & equipment
- Contract Manufacturers — The company relies on third-party contract manufacturers for the production of its medical devices; specific supplier names are not disclosed.Source
Business relationships & partnerships
- Boston IVF — Strategic partnership with an infertility center conglomerate to support the distribution and adoption of Femasys products.Source
- HRC Fertility — Strategic partnership with an infertility center conglomerate to support the distribution and adoption of Femasys products.Source
- CNY Fertility — Strategic partnership with an infertility center conglomerate to support the distribution and adoption of Femasys products.Source
Strengths
- Proprietary technology portfolio in women's reproductive healthSource
Financial risk observations and what to check
These are saved observations about business performance, not predictions. Review the company filings alongside the interpretation below. Latest stored financial period end: 2026-06-30.
Opportunity Score is currently unavailable; Wall Street Score remains independently validated.
The unavailable Opportunity Score is a separate model output. It must not be substituted with zero or inferred from the company score.
Diluted weighted-average shares increased 132.5% year over year.
Compare per-share results with total earnings and inspect the equity footnote. A change in weighted-average shares does not by itself establish the cause, the number of shares issued today, or the economic effect of a split.
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
17
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
18
Poor
Financial Strength
17
Business Quality / Moat
17
Management
0
Growth Quality
45
Risk / Durability
20
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Model Outlook
12-month model · What does the model think happens next?
Outperformance analysis is not currently available.
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
A current Opportunity Score is not available.
The 12-month model outlook is not currently available.
- •Asset quality scores strongly
- •Elevated debt risk
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
- •Debt / balance-sheet profile needs attention
Company-specific research
Questions worth answering for FEMY
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can FEMY maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •How long can FEMY fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •Is FEMY's debt load manageable relative to cash generation, interest costs and upcoming maturities?
- •What specifically needs to improve for FEMY to reach sustainable profitability?
- •What future growth or profitability would be needed to justify FEMY's current valuation?
Essential Investment Snapshot
Wall Street Score
17
Market Cap
$11.5M
P/E Ratio
-0.5
EPS
$-4.56
52-Week High
$22.20
52-Week Low
$2.00
Beta
-2.07
Shares Outstanding
2.0M
Total Revenue
$2.3M
Total Debt
$4.8M
Dividend
No current dividend
Liquidation Value / Share
$2.04
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Strong downward momentum
High movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for FEMY
Detected from reported data — verify before acting.Elevated debt risk
Total debt is at least one year of revenue • Interest coverage is below 2x • Free cash flow is negative
Community Sentiment
0 active · 0 total callsNo personal call yet on FEMY.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Proprietary technology portfolio in women's reproductive health.
Potential downside factors
- −Debt risk (elevated): Total debt is at least one year of revenue.
- −Interest coverage is below 2x.
- −Free cash flow is negative.
- −Dependence on regulatory approvals and clinical trial outcomes.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
6 historical score records availablePrevious Score
16
Sep 24, 2026
Change
+0.4
points
Current Score
17
Oct 1, 2026
Category Changes
FEMY increased 0.4 points because Asset improved by 3.7 points.
Positive Contributors
- + Asset improved by 3.7 points
Projected Score
Projected Score
10
Projected Change
-6.9 points
Preliminary comparable-period financial changes suggest decline of approximately 6.9 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$1.37
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.3M | $2.3M | $1.6M | $1.1M | ···· | ···· | ···· | ···· |
| Cost of Revenue | $1.1M | $872K | $545K | $380K | ···· | ···· | ···· | ···· |
| Gross Profit | $1.2M | $1.4M | $1.1M | $692K | ···· | ···· | ···· | ···· |
| Research & Development | $6.5M | $7.6M | $8.2M | $7.2M | ···· | ···· | ···· | ···· |
| SG&A Expenses | $12.2M | $11.1M | $10.4M | $7.5M | ···· | ···· | ···· | ···· |
| Operating Expenses | $18.8M | $19.0M | $18.9M | $15.2M | ···· | ···· | ···· | ···· |
| EBITDA | -$9.8M | -$15.9M | -$16.3M | -$13.2M | ···· | ···· | ···· | ···· |
| Operating Income | -$17.6M | -$17.6M | -$17.8M | -$14.5M | ···· | ···· | ···· | ···· |
| Interest Expense | $1.3M | $1.9M | $1.6M | $165K | ···· | ···· | ···· | ···· |
| Income Before Tax | -$11.8M | -$18.6M | -$18.8M | -$14.2M | ···· | ···· | ···· | ···· |
| Income Tax Expense | $524K | $1K | $10K | $4K | ···· | ···· | ···· | ···· |
| Net Income | -$12.3M | -$18.6M | -$18.8M | -$14.2M | ···· | ···· | ···· | ···· |
| Basic EPS | $-4.56 | $-9.40 | $-16.80 | $-18.60 | ···· | ···· | ···· | ···· |
| Basic Shares | 3.36M | 1.98M | 1.11M | 769K | ···· | ···· | ···· | ···· |
| Diluted Shares | 3.36M | 1.98M | 1.11M | 769K | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$331827
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$1.33
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
-39.0%
Cash Change
-55.1%
Margin Change
-226.3 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Debt reduced
What Weakened
- Margins contracted
- Cash position declined
Potential Score Impact
Positive indicators included debt levels. Pressure indicators included revenue growth, EPS growth, cash levels, net income margin. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue declined 18.9%. EPS declined 58.4%. Cash declined 55.1%. Total debt declined 39.0%. Net income margin declined by 226.3 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
6 historical recordsHistorical Score Chart
3 of 6 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
Medical - Instruments & SuppliesNews
Femasys Partners with SandsRx Pharmacy to Support FemaSeed® Fertility Portfolio Launch to OB/GYNs
Femasys Doubles Enrolling Sites in FemBloc FINALE Pivotal Trial for Non-Surgical Permanent Birth Control
Femasys to Exhibit at the ASRM 2026 Scientific Congress & Expo
Analyzing Haemonetics (NYSE:HAE) and Femasys (NASDAQ:FEMY)
Rumor Mill · FEMY
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial